Sector Gamma As
13F holdings for Q2 2026 · OSLO, Q8 · filed August 12, 2026
Sector Gamma As reported $461M in 13F securities across 40 holdings for Q2 2026, in a Form 13F filed August 12, 2026. The largest positions were BMY (9.1%), MRK (6.0%), Medtronic PLC SHS (6.0%). Reported value rose 8.9% from the quarter before. It opened 7 new positions, added to 19, trimmed 11 and sold out of 9.
- 13F value Q2 2026
- $461M
- Holdings
- 40
- Change vs prior quarter
- +8.9%
- Rank by 13F value
- #4,089
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Top holdings
| Stock | Value | Weight | Shares | Change in shares | Move |
|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | $41.8M | 9.1% | 726,115 | -12.3% | Trimmed |
| MRK Merck & Company Inc. | $27.9M | 6.0% | 217,008 | -16.6% | Trimmed |
| Medtronic PLC SHS | $27.6M | 6.0% | 352,437 | +25.6% | Added |
| PFE Pfizer Inc. | $24.2M | 5.2% | 1,004,215 | -8.0% | Trimmed |
| INCY Incyte Corp. | $19.4M | 4.2% | 170,753 | -14.8% | Trimmed |
| ELV Elevance Health Inc. | $17.2M | 3.7% | 44,499 | +1.2% | Added |
| BMRN BioMarin Pharmaceutical Inc. | $16.9M | 3.7% | 294,918 | +22.9% | Added |
| TMO Thermo Fisher Scientific Inc | $16.8M | 3.7% | 33,584 | New | New |
| CVS CVS Health Corporation | $16.1M | 3.5% | 155,337 | +14.8% | Added |
| IQV IQVIA Holdings Inc. | $15.1M | 3.3% | 77,944 | +93.7% | Added |
| IONS Ionis Pharmaceuticals Inc. | $15.0M | 3.3% | 189,468 | +11.8% | Added |
| BDX Becton Dickinson and Company | $14.1M | 3.1% | 93,168 | +12.8% | Added |
| ABT Abbott Laboratories | $13.4M | 2.9% | 147,444 | +68.4% | Added |
| GEHC GE HealthCare Technologies Inc. | $13.3M | 2.9% | 207,863 | +64.4% | Added |
| ZBH Zimmer Biomet Holdings Inc. | $12.3M | 2.7% | 142,307 | -8.7% | Trimmed |
| BIIB Biogen Inc. | $11.7M | 2.5% | 54,163 | -39.9% | Trimmed |
| Qiagen NV Ord Shares | $11.2M | 2.4% | 287,640 | +77.1% | Added |
| CNC Centene Corporation | $10.4M | 2.3% | 162,405 | 0% | Unchanged |
| REGN Regeneron Pharmaceuticals Inc. | $9.8M | 2.1% | 15,780 | New | New |
| BIO Bio-Rad Laboratories Inc. | $9.8M | 2.1% | 33,350 | +40.4% | Added |
| CAH Cardinal Health Inc. | $9.7M | 2.1% | 40,689 | -25.9% | Trimmed |
| AMGN Amgen Inc. | $9.5M | 2.1% | 26,281 | -44.3% | Trimmed |
| BRKR Bruker Corporation | $9.2M | 2.0% | 152,352 | -40.0% | Trimmed |
| AVTR Avantor Inc. | $9.0M | 1.9% | 906,088 | +30.3% | Added |
| PTCT PTC Therapeutics Inc. | $8.2M | 1.8% | 100,000 | +33.3% | Added |
Share positions only, at the value reported for the end of Q2 2026. Weight is the share of $461M in share positions; options and bonds count in the 13F value but not here.
Biggest buys in Q2 2026
- TMO Thermo Fisher Scientific Inc New+$16.8M
- REGN Regeneron Pharmaceuticals Inc. New+$9.8M
- IQV IQVIA Holdings Inc. Added+$7.3M
- Ascendis Pharma A/S New+$5.7M
- Medtronic PLC SHS Added+$5.6M
- ABT Abbott Laboratories Added+$5.4M
- GEHC GE HealthCare Technologies Inc. Added+$5.2M
- BSX Boston Scientific Corporation New+$5.2M
- Qiagen NV Ord Shares Added+$4.9M
- TVTX Travere Therapeutics Inc. New+$4.5M
Biggest sells in Q2 2026
- UNH UnitedHealth Group Incorporated Sold out-$9.9M
- BIIB Biogen Inc. Trimmed-$7.8M
- AMGN Amgen Inc. Trimmed-$7.6M
- GILD Gilead Sciences Inc. Sold out-$7.4M
- LNTH Lantheus Holdings Inc. Sold out-$7.1M
- BRKR Bruker Corporation Trimmed-$6.1M
- BMY Bristol-Myers Squibb Company Trimmed-$5.9M
- MRK Merck & Company Inc. Trimmed-$5.6M
- Ascendis Pharma A/S Sponsored Sold out-$4.9M
- CAH Cardinal Health Inc. Trimmed-$3.4M
The change in shares since Q1 2026, adjusted for stock splits and priced at the Q2 2026 value per share. 7 new, 19 added, 11 trimmed, 9 sold out.
Sector mix
- Health Care76.2%
- Not listed with us10.6%
- Industrials9.7%
- Consumer Staples3.5%
13F value by quarter
More holdings
| Stock | Value | Weight | Shares | Change in shares | Move |
|---|---|---|---|---|---|
| LH Labcorp Holdings Inc. | $7.3M | 1.6% | 26,019 | +36.8% | Added |
| DXCM DexCom Inc. | $6.9M | 1.5% | 102,122 | +82.0% | Added |
| Ascendis Pharma A/S | $5.7M | 1.2% | 21,305 | New | New |
| EW Edwards Lifesciences Corporation | $5.5M | 1.2% | 60,402 | 0% | Unchanged |
| SNDX Syndax Pharmaceuticals Inc. | $5.3M | 1.1% | 241,739 | -15.5% | Trimmed |
| BSX Boston Scientific Corporation | $5.2M | 1.1% | 121,128 | New | New |
| KURA Kura Oncology Inc. | $4.8M | 1.0% | 433,012 | +5.1% | Added |
| TVTX Travere Therapeutics Inc. | $4.5M | 1.0% | 80,000 | New | New |
| Crinetics Pharmaceuticals Inc Com | $4.3M | 0.9% | 114,628 | +21.7% | Added |
| TNDM Tandem Diabetes Care Inc. | $4.0M | 0.9% | 267,091 | 0% | Unchanged |
| IOVA Iovance Biotherapeutics Inc. | $4.0M | 0.9% | 968,466 | +7.6% | Added |
| CYTK Cytokinetics Incorporated | $3.8M | 0.8% | 45,000 | New | New |
| OGN Organon & Co. | $3.7M | 0.8% | 270,781 | -28.0% | Trimmed |
| ARDX Ardelyx Inc. | $3.5M | 0.8% | 686,844 | +33.1% | Added |
| NTLA Intellia Therapeutics Inc. | $3.1M | 0.7% | 185,177 | New | New |
Questions about Sector Gamma As
- What does Sector Gamma As own?
- In its Form 13F for Q2 2026, Sector Gamma As reported 40 holdings worth $461M. The five largest were BMY, MRK, Medtronic PLC SHS, PFE, INCY.
- What did Sector Gamma As buy and sell in Q2 2026?
- Sector Gamma As opened 7 new positions, added to 19, trimmed 11 and sold out of 9 compared with the quarter before.
- When did Sector Gamma As file its latest 13F?
- Form 13F is due 45 days after each quarter ends. The Q2 2026 report was due August 14, 2026 and was filed August 12, 2026.
From Form 13F filed by Sector Gamma As (SEC CIK 0001475373) for the quarter ended June 30, 2026, via the SEC's Form 13F data sets. Amendments that restate a report replace it; amendments that add holdings are included. View on SEC EDGAR · All funds · Get this as JSON